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Abstract: Covalent attachment of the nitric oxide (NO) moiety to the HIV protease inhibitor Saquinavir (Saq) produced a new
chemical entity, named Saquinavir-NO, (Saq-NO) with reduced toxicity and potent immunoregulatory influence on T lympho-
cytes. In this study, we have compared head-to-head the effects of Saq-NO and Saq on mouse and rat peritoneal macrophage
cytokine secretion and NO production upon in vitro, ex vivo and in vivo conditions. The results demonstrate that Saq-NO, but
not Saq, potently decreased interleukin (IL)-10, IL-6 and nitrite accumulation and increased the levels of IL-1b and tumour
necrosis factor (TNF) in supernatants of mouse and rat macrophage cultures in vitro. Treatment of mice with Saq-NO, but not
Saq, inhibited ex vivo secretion of IL-6 from macrophages. Consistent with these findings, Saq-NO also reduced blood levels of
IL-6 in lipopolysaccharide-treated mice. The observed inhibitory influence of Saq-NO on IL-6 generation in macrophages may
be involved in the observed antitumour and immunomodulatory effects of the drug.
Saquinavir (Saq) is the first approved protease inhibitor for
the treatment of HIV [1]. Protease inhibitors in combination
with nucleoside or non-nucleoside reverse transcriptase inhibi-
tors are the basis for the highly active antiretroviral therapy
(HAART) that is efficient in suppression of HIV replication
and reduction of clinical manifestations of the disease [2]. In
addition to antiviral effects, Saq has also been reported to pos-
sess anticancer and immunomodulatory effects [3,4], but also
to exert various side effects in patients [5].
It has been previously demonstrated that nitric oxide (NO)-
hybridization may reduce toxicity of parental compounds
while enhancing the pharmacological potency of the drugs [6].
Along this line of research, a derivative of Saq, named Saqu-
inavir-NO, (Saq-NO, OX1001) was synthesised at OncoNOx
(Copenhagen, Denmark) by covalent attachment of NO moiety
to Saq. Pre-clinical studies have proven that Saq-NO repre-
sents a new chemical entity (NCE) endowen with lower toxic-
ity, equal antiviral and superior antitumour properties than Saq
[7–12]. We have also recently shown that Saq-NO exerts a
potent immunomodulatory effect on T lymphocytes in vitro
and that it ameliorates the clinical course of MOG-induced
and PLP-induced EAE that represent two well-known pre-clin-
ical models of multiple sclerosis [13].
These data prompted us to study the influence of Saq-NO on
macrophages under different experimental conditions. Macro-
phages play a key role in immunoinflammatory responses by
releasing a wide range of soluble pro-inflammatory mediators,
including various cytokines and reactive oxygen and nitrogen
species, such as NO. Thus, we presently compared head-to-head
the influence of Saq-NO and Saq on the secretion of interleukin
(IL)-1b, IL-6, IL-10, tumour necrosis factor (TNF) and NO from
macrophages. Our results prove that, relative to cells untreated
or treated with Saq that exhibited a super-imposable profile of
cytokine and NO secretion, Saq-NO reduced the production of
NO, IL-10 and, in particular, IL-6 and it stimulated that of TNF
and IL-1b in rat and mouse macrophages in vitro. Saq-NO also
inhibited IL-6 secretion in mouse macrophages upon ex vivo
and in vivo conditions.
Materials and Methods
Reagents. RPMI-1640 medium and foetal calf serum (FCS) were
from PAA Laboratories (Pasching, Austria). DMSO, lipopolysaccharide
(LPS), interferon (IFN)-c, haemoglobin and sodium nitroprusside were
from Sigma-Aldrich (St. Louis, MO, USA). Saq was purchased from
Hoffman-La Roche. Saq-NO was obtained from OncoNOx and was
synthesised as described previously [8].
Experimental animals, cells and cell cultures. Experimental animals
(C57BL/6 mice and Dark Agouti rats) for most of the experiments were
obtained from the Animal House Facility of the Institute for Biological
Research ‘Sinisa Stankovic’, Belgrade, Serbia. The experimental
procedures were approved by the Institutional Animal Care and Use
Committee of the institute (App No 2-38/11 – 01-1211). Alternatively,
C57BL/6 mice that were used for in vivo application of LPS were
obtained from Harlan Laboratories (San Pietro al Natisone, Udine,
Italy) and were used at the animal house of the Department of Bio-
Medical Sciences of the University of Catania (Italy) in compliance
with Italian regulations on the protection of animals used for
experimental and other scientific purposes (D.L. 116/92), as well as
with EEC regulations (O.J. of E.C. L 358/1 12/18/1986) after approval
by the local ethical committee. Resident peritoneal cells were collected
by peritoneal lavage with 3-ml cold PBS, counted and were seeded in
RPMI-1640 culture medium supplemented with 5% (v/v) heat-
inactivated FCS into 24-well plates (Sartstedt, Numbrecht, Germany)
(1.5 9 106/well). After 2 hr of incubation at 37°C in a humidified
Author for correspondence: Djordje Miljkovic, Department of
Immunology, Institute for Biological Research “Sinisa Stankovic”,
Despota Stefana 142, 11000 Belgrade, Serbia (fax + 381 11 27 61 433,
e-mail georgije_zw@yahoo.com).
© 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
Basic & Clinical Pharmacology & Toxicology, 2014, 115, 499–506 Doi: 10.1111/bcpt.12268
atmosphere containing 5% CO2, peritoneal cells were washed two times
with PBS to remove non-adherent cells. The adherent cells were
considered as purified peritoneal macrophages (Mf). Mf purity was
assessed by flow cytometric analysis on a FACSCalibur flow cytometer
(BD Pharmingen) which showed that there were <5% of CD3+ cells
and CD45R+ cells in the population purified by the adhesion. Rat Mf
were stimulated for 24 hr with LPS (10 ng/ml), and murine Mf were
stimulated with LPS (10 ng/ml) + IFN-c (10 ng/ml) in the absence or
presence of Saq or Saq-NO, as indicated in the results.
In vivo treatment with Saq and Saq-NO. C57BL/6 mice were treated
for three consecutive days with Saq and Saq-NO (10 mg/kg) or
vehicle (2% DMSO in H2O). On the fourth day, peritoneal cells were
collected by peritoneal lavage with 3 ml of cold PBS per animal.
Purified cells were either stimulated with LPS (10 ng/ml) + IFN-c
(10 ng/ml) or cultivated without in vitro stimulation. Supernatants
were collected for measuring nitrite accumulation and IL-1b, TNF, IL-
6 and IL-10 production after 24 hr of cultivation.
Alternatively, Saq and Saq-NO were administered to C57BL/6 mice
i.p. at the dose of 10 mg/kg for five consecutive days. Control mice
were treated with vehicle (2% DMSO in H2O). LPS was administered
i.p. at the dose of 100 lg/mouse 1 hr after the last treatment. Mice
were killed 2 hr or 6 hr after LPS challenge. Plasma samples were
collected from the mice and used for determination of IL-6 concentra-
tion by ELISA.
Cell viability assay. In order to assess the viability of macrophages,
crystal-violet (CV) test was applied. At the end of appropriate treatments,
Mf were washed with PBS to remove non-adherent dead cells, and the
remaining cells were fixed with methanol. After staining with 1% CV
solution, the plates were thoroughly washed, and then the dye was
dissolved in 33% acetic acid. The absorbance of dissolved dye,
corresponding to the number of adherent viable cells, was measured at
570 nm with a microplate reader (LKB 5060-006; LKB, Vienna, Austria).
Assay of NO release. Nitrite accumulation, as an indirect measure of
NO release, was determined in cell culture supernatants using the Griess
reaction. In brief, triplicate aliquots of cell-free supernatants were mixed
with an equal volume of Griess reagent (a 1:1 mixture of 0.1%
naphthylethylenediamine dihydrochloride and 1% sulphanilamide in 5%
H3PO4). The absorbance at 540 nm was determined with a microplate
reader (LKB 5060-006) and compared with a standard curve for NaNO2.
ELISA test for determination of cytokines. Cytokine concentration in
cell culture supernatants was determined by sandwich ELISA using
MaxiSorp plates (Nunc, Rochild, Denmark) and anticytokine paired
antibodies according to the manufacturer’s instructions. Samples were
analysed in duplicates for murine IL-10, murine TNF, murine IL-6
and rat IL-6 (R&D, Minneapolis, MN, USA), murine IL-1b, rat IL-1b,
rat IL-10 and rat TNF (BD Biosciences, San Diego, CA, USA). The
results were calculated using standard curves made on the basis of
known concentrations of the appropriate recombinant cytokines.
Statistical analysis. Results are presented as mean  standard
deviation (S.D.) obtained in independent experiments. The significance
of the changes was evaluated by Student’s t-test (two-tailed
distribution, two-sample equal variance), and a p value <0.05 was
considered statistically significant.
Results
The effect of Saq and Saq-NO on Mf viability.
In order to assess the effect of Saq-NO on Mf viability, these
cells were isolated from rats and mice and activated with LPS
or LPS + IFN-c, respectively. The choice of the stimuli was
made according to the previously reported differential respon-
siveness of mouse and rat macrophages to exogenous activa-
tion with either LPS alone or LPS + IFN-c, respectively [14].
The stimulation lasted for 24 hr in the presence of various sin-
gle concentrations of either Saq or Saq-NO. Mf viability was
significantly affected only by 10 and 20 lg/ml Saq-NO in rat
cell cultures (fig. 1A,B). Thus, it is clear that Saq-NO exerts
limited effect on Mf viability in the concentrations that have
been shown to be effective against malignant cells [12].
The effects of Saq and Saq-NO on Mf production of IL-1b, IL-
6, IL-10 and TNF.
We next investigated whether Saq-NO affected cytokine pro-
duction in activated Mf. For that purpose, release of cytokines
IL-1b, IL-6, IL-10 and TNF from Mf stimulated with LPS or
LPS + IFN-c and cultivated for 24 hr in the presence of vari-
ous single concentrations of Saq and Saq-NO was determined.
Relative to untreated cells or cells treated with Saq, Saq-NO
potently reduced secretion of IL-10 and IL-6 (fig. 2) and effi-
ciently stimulated IL-1b (fig. 3A,B) in a dose-dependent man-
ner in mouse and rat Mf. Saq-NO also mildly but significantly
Fig. 1. Viability of rat (A) and mouse (B) peritoneal macrophages
stimulated with Saq or Saq-NO. Peritoneal macrophages were obtained
from healthy rats (A) and mice (B). The cells stimulated with lipopoly-
saccharide (LPS) (10 ng/ml) or LPS + interferon (IFN)-c (10 ng/ml)
were incubated with Saq or Saq-NO for 24 hr. Crystal-violet test was
performed in order to determine the viability of the cells. Samples
from three independent experiments were included in the analysis.
*p < 0.05 represents statistically significant difference in comparison
with control cells (not treated with Saq and Saq-NO).
© 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
500 MILJANA MOMCILOVIC ET AL.
stimulated TNF release in rat, but not mouse Mf (fig. 3C,D).
In parallel, Saq had minor effect on release of the examined
cytokines (figs 2 and 3). Thus, Saq-NO, but not Saq, potently
modulated generation of various cytokines from mouse and rat
Mf. As there was a possibility that differential effects of Saq-
NO and Saq on cytokine production were due to release of
NO from Saq-NO, several experiments were performed to test
this possibility. Firstly, release of NO from Saq-NO in cell
culture medium was measured by Griess reaction. The highest
concentration of Saq-NO used in our experiments (20 lg/ml)
did not produce measurable accumulation of nitrites after
72 hr of cultivation. Even five times higher concentration of
Saq-NO produced very low accumulation of nitrites after
72 hr of cultivation (2.9  1.4 lM, 0.8  1.1 lM and
0.9  0.8 lM for 100 lg/ml, 20 lg/ml and 0 lg/ml of Saq-
NO, respectively). Still, to demonstrate further that this trivial
release of NO did not contribute to the effects of Saq-NO, a
scavenger of NO, haemoglobin (25 lM) was applied to mac-
rophage cultures simultaneously with Saq-NO. As expected,
haemoglobin did not affect Saq-NO ability to modulate IL-1b
and IL-6 production in macrophages (data not shown).
Accordingly, simultaneous treatment of macrophages with Saq
and a donor of NO, sodium nitroprusside (200 lM) did not
mimic the effects of Saq-NO on the cytokine generation (data
not shown). Thus, it can be concluded that the difference in
effects of Saq-NO and Saq on cytokine generation in macro-
phages does not stem from the ability of Saq-NO to release
NO.
The effects of Saq and Saq-NO on Mf NO release.
Next, the effect of Saq-NO on NO synthesis in Mf was exam-
ined. The cells were stimulated with LPS or LPS + IFN-c and
cultivated in the presence of various single concentrations of
Saq or Saq-NO for 24 hr. Unlike Saq, Saq-NO efficiently
inhibited NO generation in mouse and rat Mf (fig. 4A,B).
Ex vivo effects of Saq-NO and Saq on IL-1b, IL-6, IL-10 and
TNF release from Mf.
To evaluate the ex vivo effects of Saq-NO or Saq on cytokine
production in mouse macrophages, the mice were treated with
Saq-NO, Saq or vehicle for three consecutive days, and 24 hr
after the last application, Mf were isolated from the animals.
There was no significant influence of either Saq-NO or Saq
on the number of peritoneal cells isolated from mice
(6.5  3.0, 8.2  2.1 and 8.8  3.0 9 106 in vehicle, Saq
and Saq-NO treated mice, respectively). Subsequently, Mf
were purified from the isolated cells and cultivated without
additional stimulation or in the presence of LPS + IFN-c for
24 hr. As compared with untreated cells, neither Saq-NO nor
Fig. 2. The effect of Saq and Saq-NO on IL-6 and IL-10 production in rat and mouse peritoneal macrophages. Macrophages purified from perito-
neal cells of rats activated with lipopolysaccharide (LPS) (A, C) and mice activated with LPS (10 ng/ml) + interferon (IFN)-c (10 ng/ml) (B, D)
were grown in cell culture for 24 hr in the presence or absence of Saq and Saq-NO. Then, cell-free supernatants were collected, and ELISA was
performed for determining the levels of secreted cytokines, IL-6 (A, B) and IL-10 (C, D). Results are presented as mean  S.D. of results obtained
in three independent experiments. *p < 0.05 represents statistically significant difference between Saq or Saq-NO-treated and Saq or Saq-NO
untreated cultures.
© 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
SAQUINAVIR-NO INHIBITS IL-6 PRODUCTION 501
Saq had significant effect on the cytokine generation in Mf-
stimulated ex vivo with LPS + IFN-c (fig. 5). Interestingly,
the treatment of mice with Saq stimulated IL-1b, IL-6 and
TNF production, and the treatment with Saq-NO inhibited
IL-6 production in Mf cultures that were not additionally stim-
ulated ex vivo. In addition, further differences were noted in
this assay between Saq-NO and Saq-treated cells, as spontane-
ous secretion of TNF and LPS + I FN-c-induced secretion of
IL-1b were significantly lower in Saq-NO than in Saq-treated
cells (fig. 5A,B). Thus, in vivo application of Saq-NO and Saq
had opposing effects on the cytokine release from Mf. The
only effect observed in vitro, that was replicated after in vivo
application of Saq-NO, was its inhibitory effect on IL-6.
Ex vivo effects of Saq-NO and Saq on NO production in Mf.
The ex vivo effect of either Saq-NO or Saq on NO production
in Mf was determined. Treatment of the mice with the drugs
as well as ex vivo cultivation of Mf was performed in the
same way as already described for the cytokine measurement.
Neither Saq-NO nor Saq had statistically significant influence
on NO generation by Mf, irrespectively, on the ex vivo treat-
ment (fig. 6). Thus, in vivo application of Saq-NO to mice did
not affect NO synthesis in Mf.
In vivo effects of Saq-NO and Saq on LPS-induced-IL-6
secretion.
Finally, to test the in vivo potency of Saq-NO and Saq to
modulate IL-6 generation, the mice were treated with these
agents or the vehicle and then injected with LPS to induce
cytokine release in the bloodstream. IL-6 was measured in
plasma samples. At 6 hr after LPS challenge, IL-6 blood lev-
els were significantly lower in Saq-NO-treated mice as com-
pared to either vehicle- or Saq-treated mice that exhibited
super-imposable concentrations (fig. 7). Thus, these results
further support that blockade of IL-6 synthesis/secretion repre-
sents one of the primary targets of Saq-NO in rodents.
Discussion
In this work, novel immunomodulatory effects of Saq-NO are
presented. It is shown that production of various cytokines
and NO in mouse and rat macrophages is regulated by Saq-
NO in vitro. Although the immunopharmacological profile of
Saq-NO on the cytokine secretory capacity of rodent macro-
phages appeared pleiotropic in vitro ensuing in inhibition of
IL-6, IL-10 and NO, while increasing IL-1b and, more mod-
estly TNF secretion, none of these data with exception of sig-
nificant suppression of IL-6 secretion were confirmed upon ex
vivo studies with mouse macrophages. IL-6 secretion was also
down-regulated in in vivo conditions upon LPS challenge of
mice pre-treated with Saq-NO. Thus, inhibition of IL-6 synthe-
sis/secretion from macrophages by Saq-NO is the main out-
come of our study. The ability of Saq-NO to down-regulate
IL-6 secretion from macrophages may contribute to the immu-
nomodulatory and chemotherapeutic effects of Saq-NO.
IL-6 is a small polypeptide of approximately 26 kD molecu-
lar weight that is involved in the differentiation and growth of
Fig. 3. The effect of Saq and Saq-NO on IL-1b and tumour necrosis factor (TNF) production in rat and mouse peritoneal macrophages. Macro-
phages purified from peritoneal cells of rats activated with lipopolysaccharide (LPS) (10 ng/ml) (A, C) and mice activated with LPS (10 ng/
ml) + interferon (IFN)-c (10 ng/ml) (B, D) were grown in cell culture for 24 hr in the presence or absence of Saq and Saq-NO. Then, cell-free su-
pernatants were collected and ELISAs were performed. Results are presented as mean  S.D. of results obtained in three independent experiments.
*p < 0.05 represents statistically significant difference between Saq or Saq-NO-treated and Saq or Saq-NO untreated cultures.
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a variety of cells. It has originally been described as B-cell
stimulating factor, hepatocyte stimulating factor and interferon
b2, before it was cloned and shown that all these activities
were attributable to a single molecule which did not convey
antiviral actions [15]. IL-6 binds to a receptor (IL-6R), which
consists of the actual cytokine binding part, the IL-6Ra chain,
and a second moiety, gp130, which transduces the respective
signals into the cell. IL-6 is a pleiotropic cytokine with a wide
range of biological activities in immune regulation, haemato-
poiesis, inflammation and tumour genesis. Since the discovery
of IL-6, its activities, the IL-6R system and the IL-6 signal
transduction mechanism have been further clarified. This led
to a new therapeutic approach to block the actions of IL-6 by
use of a humanized anti-IL-6R antibody (Tocilizumab) that
has been proven to be therapeutically effective for rheumatoid
arthritis, systemic juvenile idiopathic arthritis and Castleman’s
disease [16]. Therefore, the ability of Saq-NO to inhibit IL-6
secretion from macrophages adds this pharmacological prop-
erty to the previously described immunomodulatory action of
Saq-NO on T cells that primarily ensues in inhibition of
Fig. 4. The influence of Saq and Saq-NO on NO release in rat and mouse peritoneal macrophages. Rat (A) and mouse (B) macrophages were trea-
ted with Saq and Saq-NO (1.25–20 lg/ml) in the absence (medium) or presence of lipopolysaccharide (LPS) (10 ng/ml) (A) or LPS + interferon
(IFN)-c (10 ng/ml) (B). After 24 hr, supernatants were collected, and Griess assay was performed. Results are presented as mean  S.D. of results
obtained in three independent experiments. *p < 0.05 represents statistically significant difference between Saq or Saq-NO-treated and Saq or Saq-
NO untreated cultures.
Fig. 5. The effect of in vivo application of Saq and Saq-NO on IL-6, IL-10, IL-1 and tumour necrosis factor (TNF) production in mouse peritoneal
macrophages. Macrophages were purified from peritoneal cells of mice which were treated i.p. with vehicle (Ctrl) or Saq or Saq-NO for three con-
secutive days. Mf were activated with lipopolysaccharide (LPS) (10 ng/ml) + interferon (IFN)-c (10 ng/ml) (B, D) in vitro and grown in cell cul-
ture for 24 hr. Then, cell-free supernatants were collected, and ELISA was performed for determining the levels of secreted cytokines, TNF (A),
IL-1b (B), IL-6 (C) and IL-10 (D). Results are presented as mean + S.D. of results obtained from eight (Ctrl), four (Saq) or seven (Saq-NO) mice
per group. *p < 0.05 represents statistically significant difference between Saq or Saq-NO-treated and control mice (Ctrl). #p < 0.05 represents sta-
tistically significant difference between Saq and Saq-NO-treated mice.
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production of pro-inflammatory cytokines such as IL-17 and
IFN-c [13]. Inhibition of IL-6 production from macrophages
adds further value and proof of concept to the pharmacologi-
cal profile of Saq-NO and further qualifies it as a drug candi-
date of potential interest for the treatment of autoimmune
diseases. Importantly, in our previous study [13], it was also
shown that Saq-NO applied in vivo inhibited IL-6 blood levels
in mice treated with anti-CD3 antibody. Thus, Saq-NO might
be particularly efficient in autoimmune and chronic inflamma-
tory diseases in which IL-6 is a dominant pathogenic cytokine,
such as inflammatory bowel diseases, diabetes, multiple scle-
rosis, asthma and rheumatoid arthritis [17].
Macrophages are among the major players in innate immu-
nity, as well as an important antigen presenting, effector and
regulatory cells in adaptive immunity. Depending on their
activity, they can inhibit cell proliferation, induce tissue
destruction and support T cell immunity (M1 macrophages) or
they can promote cell proliferation, tissue repair and humoural
immunity (M2 macrophages) [18]. This M1/M2 polarisation is
highly important for various diseases that are immune-medi-
ated or immune-related, including cancer [19,20]. Cytokine
generation by macrophages contributes to the functions of can-
cer cells. Concentrations of Saq-NO that affected macrophage
viability were the most effective in modulation of release of
the examined cytokines. This could be explained by the effect
of Saq-NO on a signalling cascade that is common for cell
death induction and cytokine release stimulation, such as S6
kinase signalling that was shown previously important for reg-
ulation of IFN-c and IL-17 production in T cells [13]. Still,
Saq-NO regulated cytokines and NO in concentrations that did
not affect viability of macrophages, but that were previously
shown effective against transformed cells [10,12]. This is in
agreement with our previous observation of the absence of
toxic effect of Saq-NO on astrocytes and fibroblasts in vitro
[8]. Also, this implies that antitumour effects of Saq-NO could
be simultaneously achieved through direct influence on cancer
cells and indirectly through its effects on macrophages.
Tumour-associated macrophages (TAM) predominantly
belong to M2 macrophages, and they are the main inflamma-
tory population of the stroma of numerous tumours [21]. They
perform various functions to promote tumours, including
angiogenesis stimulation, matrix remodelling and adaptive
immunity suppression. Indeed, increased number of TAM in
cancer has been correlated to poor patient prognosis [21,22].
An important way in which TAM contribute to tumour growth
and progression is through release of pro-inflammatory cyto-
kines, including IL-6, TNF and IL-1b [23]. Although Saq-NO
stimulated TNF and IL-1b production in vitro, such effects
were not observed upon ex vivo conditions, and the biological
relevance of these findings is therefore unknown. In addition,
the stimulatory effect of Saq-NO on TNF secretion was only
observed in vitro from mouse but not rat macrophages and it
was of modest magnitude. On the other hand, IL-6 generation
was consistently inhibited upon in vitro, ex vivo and in vivo
conditions by Saq-NO.
Although IL-6 is easily induced in macrophages by LPS
and therefore is a typical cytokine produced by M1 macro-
phages, it also performs M2 macrophage functions. Accord-
ingly, circulating levels of IL-6 have been reported as
prognostic indicator of survival and metastasis in human can-
cers [24,25]. Importantly, IL-6 pro-proliferative and antiapop-
totic effects on tumour cells are mediated through activation
of signal transducer and activator of transcription 3 (STAT-3)
pathway, which has been identified as the leading signalling
Fig. 6. The influence of Saq and Saq-NO treatment on NO release in
mouse peritoneal macrophages. Mice were treated with vehicle (Ctrl)
or Saq or Saq-NO (10 mg/kg) for three consecutive days. On the
fourth day after the beginning of the treatment, peritoneal cells were
isolated and cultivated in the absence (medium) or presence of
LPS + interferon (IFN)-c (10 ng/ml). After 24 hr, supernatants were
collected, and Griess assay was performed. Results are presented as
mean + S.D. of results obtained from four (Saq), seven (Saq-NO) or
eight (Ctrl) mice per group.
Fig. 7. The influence of Saq-NO and Saq on IL-6 generation in mice
treated with lipopolysaccharide (LPS). Mice were treated with Saq or
Saq-NO (10 mg/kg) or with vehicle (2% DMSO in H2O) for five con-
secutive days. One hour after the last treatment, LPS (100 lg/mouse)
was applied. Mice were killed 2 hr or 6 hr after LPS treatment.
Cytokines were determined in plasma, and the results are presented as
mean + S.D. of values obtained from nine mice per group. *p < 0.05
represents statistically significant difference in comparison with control
(vehicle-treated) mice and Saq-treated mice.
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pathway for promotion of tumour growth, survival and inva-
sion [26]. In particular, recent evidence indicates a key role of
IL-6 and STAT3 in the pathogenesis of colitis-associated can-
cer that is the most serious complication of inflammatory
bowel diseases. There, IL-6 is mainly produced by tumour-
infiltrating myeloid cells, and it promotes survival and prolif-
eration of tumour-initiating cells derived from the intestinal
epithelium [27]. These effects of IL-6 are mainly STAT3-
dependent, and blockade of STAT3 signalling in intestinal
epithelial cells significantly reduces colitis-associated cancero-
genesis. Importantly, a critical role for IL-23 and its downstream
cytokines IL-17 and IL-22 were identified in the development of
colitis-associated cancers [27]. As both IL-6 and IL-17 genera-
tion are targets of Saq-NO, these data qualify this compound of
particular interest for the treatment of inflammatory bowel
diseases and prevention of colitis-associated cancers.
Moreover, IL-6 has been shown to promote M2 macrophag-
es, thus providing a positive regulatory feedback that ensures
continuous support for tumour growth [28]. As a proof of
importance of IL-6 for cancer progression, siltuximab, a chi-
meric anti-IL-6 antibody, as well as a high-affinity fully
humanized anti-IL-6 monoclonal antibody (mAb 1339) have
been shown beneficial in treatment of human cancers either as
single agents or in combination with other anticancer drugs
[29,30]. Thus, by inhibiting IL-6 secretion from macrophages,
Saq-NO might decrease IL-6 level in tumour microenviron-
ment and in that way it could contribute to tumour inhibition.
It is important to underline that the observed in vitro effects
of Saq-NO were of significantly greater magnitude than the
effects of Saq, while in vivo Saq and Saq-NO even exhibited
contrasting effects. These results further support the concept
that although Saq-NO is based on Saq with whom it shares
various properties, this agent represents a NCE endowed with
numerous properties that are distinct from those of its parental
drug. Although NO moiety is the single structural difference
between Saq and Saq-NO, here we show that NO release from
Saq-NO is not responsible for its effects on the cytokine pro-
duction in macrophages. Indeed, the amount of NO released
from Saq-NO is very low, and it has been previously shown
that it is not relevant for antitumour properties of the agent
[8,31]. In conclusion, Saq-NO is a novel and potent immuno-
modulatory agent and further studies regarding its influence
on immune cells and immune-mediated and/or immune-related
diseases are warranted.
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